Calypte Only Company with Full Menu of Tests.
Seite 125 von 144 Neuester Beitrag: 03.03.11 19:06 | ||||
| Eröffnet am: | 08.04.05 22:44 | von: Brokersince1. | Anzahl Beiträge: | 4.592 |
| Neuester Beitrag: | 03.03.11 19:06 | von: schubby1 | Leser gesamt: | 216.597 |
| Forum: | Hot-Stocks | Leser heute: | 179 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 123 | 124 | | 126 | 127 | ... 144 > | ||||
<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />
From the 10Q - China
In China, we have completed the clinical trials on our HIV rapid tests that were
conducted by the National Center for AIDS/STD Control and Prevention of the
Chinese CDC. The trials involved approximately 1,500 subjects. Based on the
results of the trials, we have submitted our oral fluid HIV-1/2 rapid test for
approval. We filed our application in late 2005 and were informed that it had
been formally accepted for evaluation by the Chinese State Food and Drug
Administration ("SFDA") in early 2006. Similar to the approval process followed
by the U.S. FDA, the SFDA has statutory timelines for responding to our
submission. IN LATE JULY 2006 THE SFDA INFORMED US THAT THEY ANTICIPATE THAT THEIR EXPERT REVIEW PANEL WILL CONSIDER OUR APPLICATION AT ITS MEETING IN SEPTEMBER 2006 . We do not know at this time whether the panel's Consideration will result in an approval or a request for more information, which we anticipate and have been collecting in an effort to expedite this process. In
the United States, this type of review is usually an iterative process.
Beijing Calypte, our joint venture with an affiliate of Marr Technologies BV,
our largest stockholder, will manage the Chinese oral fluid test product launch.
There are several large markets in China, such as those created by new laws
requiring HIV testing of military recruits and university students as part of
their admissions process, as well as a publicly-announced commitment by the
Chinese government to offer voluntary HIV testing to its entire 1.36 billion
person population. With trained non-professionals and a safe, non-invasive oral
fluid test, we expect strong demand for our initial test.
Beijing Marr has existing manufacturing facilities that have been renovated and
upgraded for the production of our AwareTM HIV-1/2 rapid oral fluid (OMT) test,
and we are preparing to comply with the GMP requirements that we must meet in
manufacturing our AwareTM line of HIV-1/2 rapid test products for sale in or
export from China. We have manufacturing equipment and personnel on-site and
expect to have the necessary GMP approval in sufficient time to produce
inventory with which to commence commercial sales upon approval of the OMT rapid
test by the SFDA. We are also evaluating existing products at these facilities
with the expectation that we will validate an existing, SFDA-approved HIV-1/2
rapid blood test; renew its GMP license; and either restart the manufacture of
that product or convert it to an AwareTM rapid test.
10Q - AFRICA - CHINA MFG. PLANS
We have completed the regulatory approval process for our Aware HIV-1/2 BSP and
OMT test in South Africa and Kenya, providing opportunities for humanitarian
organizations to use our product in their testing programs. The Mineseeker
Foundation has announced plans to use our HIV-1/2 Rapid OMT tests in a program
it plans to begin in Sub-Saharan Africa beginning late in our third quarter. In
India, we have commenced product evaluations for the military and private
sectors. We continue to pursue business opportunities in the Middle East,
targeting the UAE as our first market. We are in the process of developing
distribution channels and plan to conduct additional trials in several African
countries. The clinical trial and regulatory approval process will be on-going
through the remainder of 2006 and beyond. We are primarily targeting countries
which have been selected for funding by PEPFAR, the $15 billion President's
Emergency Plan for AIDS Relief, and currently have representation in more than
half of them. While there are different regulations and customs in each foreign
country, we believe that the regulatory process in the PEPFAR countries can
generally be completed within a few months.
Obtaining SFDA and GMP approval for and commencing manufacturing of our OMT test
in China provides an alternative manufacturing source to our Thailand
manufacturing site. Further, this approval is a critical milestone for
international sales in countries which require regulatory approval in the
country of manufacture prior to granting their own approvals. At this time,
Thailand has not approved any non-blood HIV diagnostic test and has not accepted
a submission of our OMT product for regulatory approval. We have completed
clinical trials in Thailand and are working to gain acceptance for such a
product submission. There can, however, be no assurance that Thailand will
consider approving any HIV-1/2 OMT diagnostic test.
25
<PAGE>
CALYPTE BIOMEDICAL CORPORATION AND SUBSIDIARIES
Many HIV intervention programs in developing countries are supported by foreign
funding. In the case of funding from the United States, typically through PEPFAR
or USAID, products that are not approved locally or by the USFDA may be used
provided they have a waiver issued by the USAID and CDC. We have compiled the
required data in terms of "manufacturer's claims" and independent trials for
both our OMT and blood, serum and plasma HIV-1/2 rapid tests. We have recently
been notified that our blood, serum and plasma product has been evaluated and is
approved for addition to the USAID waiver list. We are actively pursuing a USAID
waiver for our OMT product as well. We believe that obtaining a USAID waiver is
another important milestone in facilitating international sales of our rapid
tests.
Aug-06 7,80 8,13 7,75 8,05 36.650 8,05
Jul-06 7,69 7,99 7,01 7,76 36.030 7,76
Jun-06 8,79 8,85 7,45 7,55 41.418 7,55
Mai-06 8,60 8,81 8,09 8,81 61.113 8,81
Apr-06 9,00 9,66 8,32 8,60 110.010 8,60
Mrz-06 8,88 9,60 8,56 9,11 36.508 9,11
Feb-06 8,49 9,00 8,26 8,85 30.294 8,85
Jan-06 8,16 9,57 8,14 8,58 52.775 8,58
Dez-05 8,25 8,40 7,95 8,16 47.500 8,16
Nov-05 6,64 8,35 6,57 8,27 59.085 8,27
Okt-05 7,38 7,70 6,56 6,70 38.890 6,70
Sep-05 6,83 8,98 6,80 7,40 67.557 7,40
Aug-05 6,68 7,00 6,32 6,81 31.313 6,81
Jul-05 6,50 7,90 6,31 6,70 77.135 6,70
1 : 4 Stock Split
Jun-05 1,94 7,93 1,93 6,50 68.136 6,50
Mai-05 2,05 2,08 1,51 1,94 56.004 7,76
Apr-05 2,46 2,53 1,82 2,05 53.819 8,20
Mrz-05 2,68 2,82 2,40 2,54 55.459 10,16
Feb-05 2,73 2,83 2,50 2,56 41.347 10,24
Jan-05 3,00 3,02 2,65 2,68 35.920 10,72
Dez-04 2,89 2,99 2,61 2,96 79.327 11,84
Nov-04 2,66 3,15 2,66 2,90 59.347 11,60
Okt-04 2,99 3,18 2,60 2,73 52.523 10,92
Sep-04 2,93 3,23 2,69 2,99 53.419 11,96
Aug-04 2,81 3,10 2,51 2,90 47.627 11,60
Jul-04 3,39 3,42 2,36 2,78 49.919 11,12
Jun-04 2,98 3,62 2,80 3,37 86.690 13,48
Mai-04 3,03 3,15 2,70 3,00 50.510 12,00
Apr-04 3,75 3,81 2,81 3,02 97.661 12,08
Mrz-04 4,08 4,47 3,52 3,80 115.160 15,20
Feb-04 4,37 4,75 3,75 4,03 186.215 16,12
Jan-04 5,71 5,99 4,25 4,31 612.995 17,24
Dez-03 3,37 6,72 2,61 5,58 957.313 22,32
Nov-03 3,70 3,79 3,10 3,45 51.705 13,80
Okt-03 3,65 4,41 3,55 3,79 100.886 15,16
Sep-03 3,55 4,01 3,11 3,69 125.823 14,76
Aug-03 2,63 3,65 2,26 3,54 108.604 14,16
Jul-03 2,96 3,45 2,31 2,59 63.813 10,36
Jun-03 2,37 3,50 2,36 3,03 87.138 12,12
Mai-03 2,54 2,73 2,20 2,39 47.771 9,56
Apr-03 2,12 2,83 2,09 2,55 70.761 10,20
Mrz-03 1,96 2,44 1,77 2,13 32.433 8,52
Feb-03 1,64 1,97 1,52 1,95 28.594 7,80
Jan-03 1,34 1,65 1,25 1,64 21.580 6,56
Dez-02 1,29 1,67 1,27 1,35 14.057 5,40
Nov-02 1,11 1,41 1,11 1,30 23.345 5,20
Okt-02 0,95 1,19 0,93 1,14 25.873 4,56
Sep-02 1,20 1,20 0,89 0,95 17.285 3,80
Aug-02 1,13 1,31 1,06 1,20 6.445 4,80
Jul-02 1,41 1,49 1,02 1,14 8.131 4,56
Jun-02 1,40 1,49 1,24 1,40 8.680 5,60
Mai-02 1,51 1,60 1,36 1,41 8.340 5,64
Apr-02 1,48 1,64 1,32 1,51 15.631 6,04
Mrz-02 1,56 1,68 1,42 1,48 8.990 5,92
Feb-02 1,70 1,79 1,45 1,55 10.716 6,20
Jan-02 1,51 1,86 1,50 1,65 19.914 6,60
Dez-01 1,46 1,73 1,40 1,52 18.350 6,08
Nov-01 1,45 1,61 1,40 1,50 12.085 6,00
Okt-01 1,37 1,83 1,20 1,50 13.360 6,00
Sep-01 1,45 1,54 0,96 1,37 12.500 5,48
Aug-01 1,85 1,89 1,36 1,40 9.665 5,60
Jul-01 1,83 1,90 1,51 1,79 13.566 7,16
Jun-01 2,04 2,34 1,67 1,78 17.123 7,12
Mai-01 2,00 2,49 1,85 2,10 19.452 8,40
Apr-01 2,28 2,50 1,91 2,02 18.931 8,08
Mrz-01 2,69 3,22 2,00 2,25 29.731 9,00
Feb-01 2,47 2,56 2,41 2,50 40.400 10,00
* Dividenden und Splits berücksichtigt.
Im Juni det split 2005 also 1:4 wer da drin war auch nicht rosig oder?
Datum Eröffnung Hoch Tief Schluß Ø Volumen Adj. Schluß*
Aug-06 7,22 7,22 6,98 7,22 0 7,22
Jul-06 7,34 7,42 6,61 7,24 95 7,24
Jun-06 6,74 7,33 6,28 7,33 27 7,33
Mai-06 8,19 8,20 6,42 6,72 33 6,72
Apr-06 8,43 8,47 7,50 8,19 122 8,19
Mrz-06 7,86 8,58 7,86 8,33 10 8,33
Feb-06 8,86 9,39 7,69 8,10 73 8,10
Jan-06 7,35 9,00 7,31 9,00 53 9,00
Dez-05 11,39 11,80 6,52 7,35 578 7,35
Nov-05 9,10 11,37 8,59 11,37 240 11,37
Okt-05 7,81 9,30 7,36 9,30 93 9,30
Sep-05 7,43 7,70 7,21 7,70 9 7,70
Aug-05 8,78 9,01 7,02 7,29 15 7,29
Jul-05 8,21 9,90 8,21 8,96 300 8,96
Jun-05 6,40 8,22 6,40 8,06 199 8,06
Mai-05 6,11 6,77 6,11 6,70 70 6,70
Apr-05 5,60 6,50 5,33 6,12 52 6,12
Mrz-05 5,00 5,66 4,70 5,50 53 5,50
Feb-05 4,15 5,46 4,15 5,10 120 5,10
Jan-05 4,80 4,80 4,10 4,30 72 4,30
Dez-04 5,10 5,40 4,90 4,90 84 4,90
Nov-04 5,20 5,60 5,10 5,10 0 5,10
Okt-04 5,00 5,40 4,40 5,20 42 5,20
Sep-04 5,05 5,35 5,00 5,00 0 5,00
Aug-04 6,30 6,30 4,00 5,00 49 5,00
Jul-04 7,80 7,80 5,85 6,20 67 6,20
Jun-04 5,80 7,80 5,50 7,80 625 7,80
Mai-04 7,25 7,25 5,40 5,80 139 5,80
Apr-04 7,50 8,40 7,30 7,30 258 7,30
07 Aug 2006, 11:12 AM EDT
Msg. 68985 of 68985
(This msg. is a reply to 68984 by roy_hinkley.)
Jump to msg. #
I can imagine, roy. after having read I can only state:
bad - worse - calypte
c040.gif
31 Jul 2006, 02:07 PM EDT
Msg. 740 of 745
(This msg. is a reply to 738 by roy_hinkley.)
Jump to msg. #
of course: delisting roy.
to all, who have defended themselves successful for more than 2 years against the truth:
congratulation for stubborness and dullness!!!
e030.gif
und dann später mit der allerletzten kohle nochmals nachzukaufen bei 0,11$. du hast es wirklich nicht besser verdient. sag "tschüß" zu deinem letzten geld...ich hätte an deiner stelle wenigstens erst mal das filing abgewartet mit den neuen aktienangaben. aber ich glaube, du lernst es nie. selbst dann nicht, wenn der allerletzte cent mit caly verzockz ist. du bist bedauernswert lucky, wenigstens kannst du über deinen verlust noch lachen, wie ich sehe. sehr schön...muahahahahahahaha
junge, junge, ich weiß wie toll caly ist. man sieht es ja: die vermeintlichen zulassungen weltweit erzeugen milliardenumsätze...muhahahahahahaha und vor allem hohe gewinne, darum habt ihr sicherlich auch das stärkste quartalergebnis eurer geschichte hingelegt...prust!!!
broker deine ignoranz und dein gespielter optimismus bleiben unerreicht. dabei weiß du ganz im tiefen inneren, wie haushoch du mit deiner caly-sturheit baden gegangen bist...
lieber so, als ein titel zu haben, der zwar sehr liquide ist, mit dem du aber 95% im minus bist, G A L E????
bei 8,30$ steige ich pari aus trinity aus, du vollblut-investor. trinity hat nämlich was zu bieten im gegensatz zu caly: umsätze und sogar auch gewinne.
weißt du überhaupt noch, wie man das wort schreibt, lucky? sein mal ehrlich!
Da kommt es auf den Inhalt des CC`s an ...
Wird ganz bestimmt sehr spannend,nach dem was alles in den letzten Monaten oder im letzten Monat so alles verkündet worden ist...
Aug 13-18 - 16th International AIDS Conference, in Toronto, Canada.
Auszüge aus dem Bericht
>> 2003: US President George Bush unveils plans to spend 15 billion dollars over five years to combat AIDS in Africa and Caribbean. First HIV vaccine to undergo a full trial proves to be a flop. New WHO Director General Lee Jong-Wook names AIDS as his top priority, calls for three million poor people to get access to antiretrovirals by end of 2005. In a landmark gesture, Chinese Prime Minister Wen Jiabao becomes first premier of his country to publicly shake the hands of an AIDS patient. Cost of antiretrovirals plummets, helped by World Trade Organisation (WTO) deal allowing poor, vulnerable countries to import generics.
>> 2004: South Africa finally starts to provide free antiretrovirals in hospitals. G8 summit calls for a Global HIV Vaccine Enterprise that will beef up coordination and exchanges of information among the world’s vaccine scientists.
>> 2005: WHO’s "Three by Five" initiative falls far short of goal, reaching only 1.3 million out of a hoped-for three million. But it is also praised for mobilising political commitment and funds and building medical infrastructure.
>> 2006: February - China issues first policy guidelines on dealing with AIDS epidemic, including requirement for local governments to offer free drugs and testing.
March - Lancet study says the number of new HIV infections in southern India has plunged by a third over four years, apparently due to safe-sex practices.
May - UNAIDS says more than 25 million people have now been killed by AIDS. But it revises downwards to 38.6 million the total living today with HIV/AIDS and says the overall infection rate has stabilised.
June - UN members set goal of universal access to HIV/AIDS care by 2010.
Aug 13-18 - 16th International AIDS Conference, in Toronto, Canada.
~~~~~~~~~~~~~~~~
and a few numbers
* The Global Fund to Fight AIDS, Tuberculosis and Malaria, founded in 2001, illustrates a growing international commitment to address the pandemic, even though it remains well short of the $7 billion to $10 billion annual budget recommended by UN Secretary General Kofi Annan. See: www.theglobalfund.org/en/ for more information.
* By the end of 2005, 40.3 million people were living with HIV/AIDS, including 17.5 million women and 2.3 million children under the age of 15.
* 4.9 million people became newly infected with HIV in 2005, including 700,000 children. Of these, 3.2 million new infections occurred in sub-Saharan Africa.
* In 2005 alone, a total of 3.1 million people died of HIV/AIDS-related causes.
* World-wide, only one in ten persons infected with HIV has been tested and knows his/her HIV status.
* Ninety-six percent of people with HIV live in the developing world, most in sub-Saharan Africa. The epidemic continues to grow in this region, with nearly a million new infections between 2003 and 2005.
* In some African countries, three quarters of those infected are women -- many of whom have not had more than one sexual partner.
* An estimated 5 to 6 million people in low- and middle-income countries will die in the next two years if they do not receive antiretroviral treatment (ART). At the end of 2005, only one in seven Asians and one in ten Africans who need ART were receiving it.
* In six African countries, (Botswana, Lesotho, Namibia, South Africa, Swaziland and Zimbabwe), more than one in five of all pregnant women have HIV/AIDS. In Swaziland, nearly 40 per cent of pregnant women are HIV-positive.
* Without prevention efforts, 35 per cent of children born to an HIV positive mother will become infected with HIV. At least a quarter of newborns infected with HIV die before age one, and up to 60 per cent will die before reaching their second birthdays.
* Injecting drug use and commercial sex work are fuelling the epidemic across Asia and Eastern Europe, and few countries are sufficiently reaching out to these marginalized groups or addressing the poverty that often underlies these behaviors.
* By the end of 2005, women accounted for nearly half of all people living with AIDS worldwide, and represent almost 60 per cent of infections in sub-Saharan Africa.
* Worldwide, 62 per cent of infected young people are girls, and that number soars to 77per cent in sub-Saharan Africa.
* The Caribbean is the region with the world's second-highest HIV prevalence rate.
* There is some reason for optimism in the Caribbean region, where overall HIV prevalence remained the same in 2005 as in 2003.
source: Global Health Council at:
globalhealth.org/
Hier der Kursverlauf und Umsatz in Deutschland!
Datum Eröffnung Hoch Tief Schluß Ø Volumen Adj. Schluß*
Aug-06 0,01 0,01 0,01 0,01 0 0,01
Jul-06 0,01 0,01 0,01 0,01 16.000 0,01
Jun-06 0,01 0,03 0,01 0,01 118.565 0,01
Mai-06 0,00 0,01 0,00 0,00 0 0,00
Apr-06 0,00 0,00 0,00 0,00 0 0,00
Mrz-06 0,00 0,01 0,00 0,00 0 0,00
Feb-06 0,01 0,01 0,00 0,00 0 0,00
Jan-06 0,00 0,01 0,00 0,01 0 0,01
Dez-05 0,01 0,01 0,00 0,00 0 0,00
Nov-05 0,00 0,01 0,00 0,01 0 0,01
Okt-05 0,01 0,01 0,00 0,00 0 0,00
Sep-05 0,01 0,01 0,00 0,01 0 0,01
Aug-05 0,01 0,01 0,00 0,00 0 0,00
Jul-05 0,01 0,01 0,01 0,01 0 0,01
Jun-05 0,01 0,01 0,00 0,01 0 0,01
Mai-05 0,01 0,01 0,01 0,01 0 0,01
Apr-05 0,01 0,01 0,01 0,01 0 0,01
Mrz-05 0,01 0,02 0,01 0,01 0 0,01
Feb-05 0,01 0,02 0,01 0,01 0 0,01
Jan-05 0,01 0,02 0,01 0,01 0 0,01
Dez-04 0,02 0,02 0,01 0,02 0 0,02
Nov-04 0,03 0,03 0,02 0,02 0 0,02
Okt-04 0,04 0,04 0,03 0,03 0 0,03
Sep-04 0,05 0,08 0,03 0,04 0 0,04
Aug-04 0,08 0,09 0,06 0,06 0 0,06
Jul-04 0,11 0,11 0,07 0,08 0 0,08
Jun-04 0,17 0,18 0,10 0,11 0 0,11
Mai-04 0,23 0,25 0,17 0,17 0 0,17
Apr-04 0,32 0,32 0,23 0,29 0 0,29
Mrz-04 0,30 0,30 0,29 0,29 0 0,29
Innerhalb 3 Jahren von 0,32 auf 0,0 ???? hmmm doch Supi oder?
Grüße Lucky
unbenannt.bmp
Ich kann mich noch daran erinnern, wo Joelü uns erzählen wollte, wie gut Augrid oder Agri ist.....
Jetzt SCRH ??
würde aber auch deine flexibilität, was einsicht anbelangt, widerspiegeln, wenn du ein depot hast, mit welchem du nur in deutschland handeln kannst...muhahhaahahahaha
1)augrid wird noch an den pinksheets gehandelt (bist du dir sicher, dass calypte bei der wirtschaftlichen stärke nicht auch bald dort gehandelt wird? muhahahahahaha?
2) ich habe augrid damals empfohlen. mit dem UNTERSCHIED ZU DIR habe ich mweine fehler mit der fehlinvestition schon nach 6 monaten eingesehen. DU HAST DEINEN FEHLER ABER IMMER NOCH NICHT EINGESEHEN...UND DAS NACH JAHREN!!!! muhahahahaha
du und lucky, ihr seid so ziemlich die größten ignoranten, blindgänger und sturköpfe, die mir je vorgekomemn sind.
ihr würdet es nicht mal dann akzeptieren, dass ihr haus und hof verloren habt, wenn GALE euch persönlich die hand reichen würde und sagen würde, dass er euch über jahre beschissen hat....oh mann oh mann, was für eine volksbelustigung...muhahahahahaha
By Linda <?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />
1. Company received order from the UAE for 100,000 over the counter tests today.
2. The issue of foreclosure is null, as with the exercise of the warrants, the condition was lifted and the exclusion to foreclose based on AMEX listing is no longer effective or possible.
3. Orders are paid for in advance, therefore, all funding received from sales goes toward producing and filling orders.
4. With today's amount in cash, the company can operate two to three months.
5. The company has two agents out seeking financing for the company.
6. They are in negotiation with the individuals involved in the subscription agreement to pay the balance of the agreement. Remedy, in the event of continued breach has not yet been determined.
Capitalizing company: More flexibility on the otcbb to capitalize. Major opportunities blooming for tests. New challenges, subscription agreement (2) to sell 3,000,000 worth of stock. $495,000 has been funded to date. They breached agreement and are working them. Marr agreement, can issue one more policy note for $500,000. During 2006, offered to amend the exercise price for warrants---April 5, 2005 note, agreed to exercise all their warrants. Helped strengthen balance sheet. 25,000,000 shares of stock $258,000 of cash and retired 3.5 million of outstanding date.
7. They are exhibiting at the 16th AIDS Global Conference in Toronto this week.
8. Mineseeker order to be filled in ten to twelve months. They have the ability to fill it through outsourcing, though can do more through the China Plant.
9. Expected sixty to ninety days for plant GMP certification and production in China, pending approval.
10. SFDA states Calypte will be on the docket in October for the Committee decision on approval in China. SFDA is working hard to get it on the docket in September. Development in Chinese market. Chinese market is expected to grow to 12,000,000,000 in 2003 to 150,000,000 2011 On oral rapid test in China, expect to acheive 15% in the market within two years. Sales and marketing program building relationships with key presons in China...opens doors to other over the counter versions of Aware products.
11. Product based on the ANI technology to be applied for and available on the U.S. market in mid to late 2007 for professional use. 2008 for OTC use.
12. Developing other tests for single step use with the CDC
13. India - Indian Market: Underplayed....5.1 million infections, second number to South Africa. 20% annual growth in diagnostic. Military private and government. Evaluations undergoing, expects approval for all those three markets. Only alternative HIV oral rapid test available in India. 15-25 percent of market, w/n 3 years......
14. OTC Market: OTC Market. Company selling test in UAE, received orders for 100,000 units today. Begun process for OTC test in Europe, particularly in Russia. Filed for approval in Russia.......work with Marr for sales
15. Financing does not affect production and sales of product. Customers pay first and the payment is made in advance to the outsource plant.
16. Regional and Professional Markets: Regional and Pro Markets: Markets expected to grow by 10% annual. Focusing on key countries for growth: Begun selling in South Africa, will be aware, first order from Mineseeker, expected 1,000,000 tests over next twelve months, expect 5 million tests annually. Approvals in Kenya, Maylaysia, Zimbabwe, South Africa
17. Blood test approved with USAID, OMT is in application with USAID for Pepfar funding.
18. BED test: 2nd quarter, revised protocal issued by CDC. Test's design and use and interpretation will continue to evolve as experience is gained with use of the test.
19. Continue to trade on AMEX, for now as HIV. Plan to trade on the OTC bulletin board, pink sheets as well.......adverse impact was a surprise of AMEX, will not affect shipments and deadlines. Not focusing on short termed sentiments of where the stock is and at what price. As long as listed, doesn't expect long termed reaction with market place. Will execute on sound business plan envisioned in 2005....
20. Have and are expecting orders.
Yes.
1. The issue of default was resolved, due to the clause of not being listed on the AMEX and it is not an issue.
2. The company can continue to market, take orders and sell tests with their current financial condition...as orders are paid in advance.
3. They are seeking financing and the $15 to $20 million they are seeking is projected to get them through two years.
4. This is a long termed investment with long termed goals.
5. They are not responsible for SFDA governmental timelines.
I'm good with it....
Ich bin überzeugter denn je...............
mit dem gegenwärtigen cash kommen sie 2-3 monate hin. man will weiter 15-20 millionen auftreibe, gegen neue aktien natürlich...
ICH BIN AUCH ÜBERZEUGTER DENN JE, DASS IHR NOCH IM SEPTEMBER DIE 0,05$ SEHT!!! DESWEITEREN BIN ICH DAVON ÜBERZEUGT, DAS CALY BALD EIN SUBPENNYSTOCK SEIN WIRD UND DAS SPÄTESTENS "==/ EIN WEITERE GROSSER REVERSE-SPLITT KOMMT!!!
GUTE NACHT!
Und wieder zwei Schmarotzer mehr auf der Payroll, die sich von euren Aktienkäufen fett machen *ggg*
5. The company has two agents out seeking financing for the company.
Aber egal - alles wird gut!
Es genügt nicht, keine Gedanken zu haben, man muss auch unfähig sein, sie auszudrücken.
| Calypte Launches Sales Initiative in Middle East |
LAKE OSWEGO, Ore., Aug. 10 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV), medical diagnostic tests manufacturer for the professional point of care (PRO) and over the counter (OTC) segments of the market primarily for the detection of antibodies to the human immunodeficiency virus (HIV), announced today that it has received an order for 100,000 of its over-the-counter (OTC) version of the Aware(TM) Oral Fluid HIV-1/2 Rapid Diagnostic Test. Joseph and Gionis, Calypte's exclusive distributor in the Middle East, is initially focusing on the United Arab Emirates (UAE) with this order. The value of this order is in excess of $250,000. Dr. Gionis, President of Joseph and Gionis, commented, "Joseph and Gionis has been actively involved with Calypte since the introduction of this first-ever Over-the-Counter (OTC) HIV test at Arab Health, the largest Healthcare Exhibition in the Middle East, held in Dubai last January. I am pleased to see the progress we are now realizing. This first sizable order will go into the UAE. At the same time, we are continuing to obtain regulatory approvals throughout the region and expect to launch this OTC test into additional countries in the coming months." Dr. Gionis concluded, "While we are all saddened by the war in the Middle East, HIV/AIDS continues to be a major focus and we expect to exceed our one-year targets -- delivering at least 700,000 tests into a minimum of 7 countries in the region." Roger I. Gale, Chairman and Chief Executive Officer of Calypte stated, "We are starting to penetrate those markets where we have focused our initial regulatory efforts, including South Africa and now the UAE. It is gratifying to see the results and to be able to focus on the positive challenges of ramping up our manufacturing efforts. I look forward to a having a growing and productive relationship with Joseph and Gionis, as this organization continues to utilize its expertise to facilitate the regulatory process in additional countries within its territory. We will continue to keep you posted as we expand our penetration into the Middle East." About Joseph and Gionis: Joseph and Gionis (www.josephandgionis.com ) is a global biotechnology consulting and distribution firm with offices in Newport Beach, California and the UAE, specializing in new scientific developments which contribute to public health and welfare. Joseph and Gionis is Calypte's exclusive distributor for 21 Middle Eastern countries with a population of approximately 465 million people. According to the December 2004 UNAIDS report, there are between 230,000 and 1.5 million adults and children living with HIV within this region, of which nearly half are women. About Calypte Biomedical: Calypte Biomedical Corporation (www.calypte.com ) is a U.S.-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases such as the HIV-1 BED Incidence EIA and new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases. Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2005 and its subsequent filings with the SEC. Company Contact: Investor Relations Contact: Theodore R Gwin, Tim Clemensen, Chief Financial Officer Rubenstein Investor Relations (971) 204-0282 Phone: (212) 843-9337 email: tgwin@calypte.com email: tclemensen@rubensteinir.comSOURCE Calypte Biomedical Corporation -0- 08/10/2006 /CONTACT: Theodore R Gwin, Chief Financial Officer of Calypte BiomedicalCorporation, +1-971-204-0282, tgwin@calypte.com; or Investor Relations, TimClemensen, +1-212-843-9337, tclemensen@rubensteinir.com, of RubensteinInvestor Relations for Calypte Biomedical Corporation/ /Web site: http://...nbsp; http://www.josephandgionis.com / (HIV)CO: Calypte Biomedical CorporationST: Oregon, California, United Arab EmiratesIN: IDC HEA MTC BIOSU: CONBR-- NYTH009 --7100 08/10/2006 07:30 EDT http://www.prnewswire.com |
ach doch!!! 250.000$. das 5-fache des letzten caly-quartalsumsatz!!!
naja, wenigstens etwas. wird aber wohl nicht viel ausrichten am kurs, da die cash-burn-quote bei über 3.500.000$ liegt pro quartal...
da müssen mal millionen-umsätze kommen, sonst ist der RS ganz schnell da!!!